[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489347":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":56,"centralContacts":57,"locations":67,"responsibleParty":424,"collaborators":426,"id":429,"slug":430,"hasResults":431,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":56,"eligibilityCriteria":435,"healthyVolunteers":431,"sex":436,"minAge":437,"maxAge":56,"enrollmentInfo":438,"targetDuration":56,"studyType":441,"phases":442,"briefSummary":444,"conditions":445,"keywords":449,"overallStatus":70,"whyStopped":56,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":467},{"fullName":5,"class":6},"K36 Therapeutics, Inc.","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A (Single agent): KTX-1001 + dexamethasone","EXPERIMENTAL","Cohort A1 (single agent): KTX-1001 at RP2D1 + dex Cohort A2 (single agent): KTX-1001 at RP2D2 + dex",[13],"Drug: Cohort A1 & A2: KTX-1001",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B (Mezigdomide): KTX-1001 + Mezigdomide + dex","Cohort B1 (Mezigdomide): KTX-1001 at RP2D1 + Mezigdomide + dex Cohort B2 (Mezigdomide):: KTX-1001 at RP2D2 + Mezigdomide + dex",[18],"Drug: Cohort B1 & B2: KTX-1001+Mezigdomide",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort C (carfilzomib\u002FKYPROLIS®): KTX-1001 + carfilzomib + dex","Cohort C1 (carfilzomib\u002FKYPROLIS®): KTX-1001 at RP2D1 + carfilzomib + dex Cohort C2 (carfilzomib\u002FKYPROLIS®): KTX-1001 at RP2D2 + carfilzomib + dex",[23],"Drug: Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)",{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort D (pomalidomide): KTX-1001 + pomalidomide + dex","Cohort D (pomalidomide): KTX-1001 at RP2D2 + pomalidomide + dex",[28],"Drug: Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)",[30,38,44,50],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Cohort A1 & A2: KTX-1001","KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly",[9],[36,37],"KTX-1001","Dexamethasone",{"type":31,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Cohort B1 & B2: KTX-1001+Mezigdomide","Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly",[15],[43],"Mezigdomide",{"type":31,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)","Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle",[20],[49,37],"Carfilzomib (KYPROLIS®)",{"type":31,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)","Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle",[25],[55,37],"Pomalidomide (Pomalyst, Imnovid)",null,[58,63],{"name":59,"role":60,"phone":61,"phoneExt":56,"email":62},"Soo Bang, MHSA","CONTACT","1-347-342-7199","sbang@k36tx.com",{"name":64,"role":60,"phone":65,"phoneExt":56,"email":66},"Raymond Burgos, BSBA","1-774-276-6623","rburgos@k36tx.com",[68,90,107,124,139,150,167,184,202,218,234,250,267,283,301,317,331,346,357,375,390,408],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic","RECRUITING","San Francisco","California","94143","United States","US",{"type":77,"coordinates":78},"Point",[79,80],-122.41942,37.77493,{"lat":80,"lon":79},[83,87],{"name":84,"role":60,"phone":85,"phoneExt":56,"email":86},"Phu Lam","415-858-7994","phu.lam@ucsf.edu",{"name":88,"role":89,"phone":56,"phoneExt":56,"email":56},"Alfred Chung, MD","PRINCIPAL_INVESTIGATOR",{"facility":91,"status":70,"city":92,"state":93,"zip":94,"country":74,"countryCode":75,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Mayo Clinic Hospital - Florida","Jacksonville","Florida","32224",{"type":77,"coordinates":96},[97,98],-81.65565,30.33218,{"lat":98,"lon":97},[101,105],{"name":102,"role":60,"phone":103,"phoneExt":56,"email":104},"Ahsan Rasheed","904-953-2000","rasheed.ahsan@mayo.edu",{"name":106,"role":89,"phone":56,"phoneExt":56,"email":56},"Vivek Roy, MD",{"facility":108,"status":70,"city":109,"state":110,"zip":111,"country":74,"countryCode":75,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"The Winship Cancer Institute of Emory University","Atlanta","Georgia","30322",{"type":77,"coordinates":113},[114,115],-84.38798,33.749,{"lat":115,"lon":114},[118,122],{"name":119,"role":60,"phone":120,"phoneExt":56,"email":121},"Geraldine Onwuzor","404-778-5144","chika.geraldine.onwuzor@emory.edu",{"name":123,"role":89,"phone":56,"phoneExt":56,"email":56},"Sagar Lonial, MD, FACP",{"facility":125,"status":70,"city":126,"state":127,"zip":128,"country":74,"countryCode":75,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":77,"coordinates":130},[131,132],-71.05977,42.35843,{"lat":132,"lon":131},[135,138],{"name":136,"role":60,"phone":137,"phoneExt":56,"email":56},"Andrew Yee, MD","617-724-4000",{"name":136,"role":89,"phone":56,"phoneExt":56,"email":56},{"facility":140,"status":70,"city":126,"state":127,"zip":141,"country":74,"countryCode":75,"cosmosGeoPoint":142,"geoPoint":144,"contacts":145},"Dana-Farber Cancer Institute","02215",{"type":77,"coordinates":143},[131,132],{"lat":132,"lon":131},[146,149],{"name":147,"role":60,"phone":56,"phoneExt":56,"email":148},"Yuxin Liu, MD","yuxin_liu@dfci.harvard.edu",{"name":147,"role":89,"phone":56,"phoneExt":56,"email":56},{"facility":151,"status":70,"city":152,"state":153,"zip":154,"country":74,"countryCode":75,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Mayo Clinic - Transplant Center - Rochester","Rochester","Minnesota","55905",{"type":77,"coordinates":156},[157,158],-92.4699,44.02163,{"lat":158,"lon":157},[161,165],{"name":162,"role":60,"phone":163,"phoneExt":56,"email":164},"Thomas Nelson","855-776-0015","nelson.thomas2@mayo.edu",{"name":166,"role":89,"phone":56,"phoneExt":56,"email":56},"David Dingli, MD, PhD",{"facility":168,"status":70,"city":169,"state":170,"zip":171,"country":74,"countryCode":75,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":77,"coordinates":173},[174,175],-74.04347,40.88593,{"lat":175,"lon":174},[178,182],{"name":179,"role":60,"phone":180,"phoneExt":56,"email":181},"Palka Anand","551-996-3040","Palka.Anand@hmhn.org",{"name":183,"role":89,"phone":56,"phoneExt":56,"email":56},"David S Siegel, MD, PhD",{"facility":185,"status":70,"city":186,"state":186,"zip":187,"country":74,"countryCode":75,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Memorial Sloan-Kettering Cancer Center","New York","10065",{"type":77,"coordinates":189},[190,191],-74.00597,40.71427,{"lat":191,"lon":190},[194,197,200],{"name":195,"role":60,"phone":56,"phoneExt":56,"email":196},"Mary Silverberg","silverb1@mskcc.org",{"name":198,"role":60,"phone":56,"phoneExt":56,"email":199},"Sharon Kim","kims13@mskcc.org",{"name":201,"role":89,"phone":56,"phoneExt":56,"email":56},"Saad Usmani, MD, FACP",{"facility":203,"status":70,"city":204,"state":205,"zip":206,"country":74,"countryCode":75,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Atrium Health, Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":77,"coordinates":208},[209,210],-80.84313,35.22709,{"lat":210,"lon":209},[213,216],{"name":214,"role":60,"phone":56,"phoneExt":56,"email":215},"Missy Leahy","melissa.leahy@advocatehealth.org",{"name":217,"role":89,"phone":56,"phoneExt":56,"email":56},"Cindy Varga, MD",{"facility":219,"status":70,"city":220,"state":205,"zip":221,"country":74,"countryCode":75,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"Duke University Hospital","Durham","27705",{"type":77,"coordinates":223},[224,225],-78.89862,35.99403,{"lat":225,"lon":224},[228,232],{"name":229,"role":60,"phone":230,"phoneExt":56,"email":231},"Jen Tichon","919-660-7262","jennifer.tichon@duke.edu",{"name":233,"role":89,"phone":56,"phoneExt":56,"email":56},"Cristina Gasparetto, MD",{"facility":235,"status":70,"city":236,"state":237,"zip":238,"country":74,"countryCode":75,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":77,"coordinates":240},[241,242],-75.16362,39.95238,{"lat":242,"lon":241},[245,248],{"name":246,"role":60,"phone":56,"phoneExt":56,"email":247},"Sara Whittington","sara.whittington@pennmedicine.upenn.edu",{"name":249,"role":89,"phone":56,"phoneExt":56,"email":56},"Ed Stadtmauer, MD",{"facility":251,"status":70,"city":252,"state":253,"zip":254,"country":74,"countryCode":75,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"Tennessee Oncology","Nashville","Tennessee","37203",{"type":77,"coordinates":256},[257,258],-86.78444,36.16589,{"lat":258,"lon":257},[261,265],{"name":262,"role":60,"phone":263,"phoneExt":56,"email":264},"Austin Windsor","629-278-3554","awindsor@tnonc.com",{"name":266,"role":89,"phone":56,"phoneExt":56,"email":56},"Jesus Berdeja, MD",{"facility":268,"status":70,"city":269,"state":270,"zip":271,"country":74,"countryCode":75,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center","Dallas","Texas","75235",{"type":77,"coordinates":273},[274,275],-96.80667,32.78306,{"lat":275,"lon":274},[278,282],{"name":279,"role":60,"phone":280,"phoneExt":56,"email":281},"Aimaz Afrough, MD","833-722-6237","aimaz.afrough@utsouthwestern.edu",{"name":279,"role":89,"phone":56,"phoneExt":56,"email":56},{"facility":284,"status":70,"city":285,"state":286,"zip":287,"country":288,"countryCode":289,"cosmosGeoPoint":290,"geoPoint":294,"contacts":295},"University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital)","Toronto","Ontario","M5G 2C4","Canada","CA",{"type":77,"coordinates":291},[292,293],-79.39864,43.70643,{"lat":293,"lon":292},[296,299],{"name":297,"role":60,"phone":56,"phoneExt":56,"email":298},"Saima Dean","saima.dean@uhnresearch.ca",{"name":300,"role":89,"phone":56,"phoneExt":56,"email":56},"Suzanne Trudel, MSc, MD",{"facility":302,"status":70,"city":303,"state":304,"zip":56,"country":304,"countryCode":305,"cosmosGeoPoint":306,"geoPoint":310,"contacts":311},"Universitaire de Lille","Villeneuve-d'Ascq","France","FR",{"type":77,"coordinates":307},[308,309],3.16664,50.61669,{"lat":309,"lon":308},[312,316],{"name":313,"role":60,"phone":314,"phoneExt":56,"email":315},"Salomon Manier, MD","03 59 50 75 69","Salomon.manier@chru-lille.fr",{"name":313,"role":89,"phone":56,"phoneExt":56,"email":56},{"facility":318,"status":70,"city":319,"state":56,"zip":56,"country":304,"countryCode":305,"cosmosGeoPoint":320,"geoPoint":324,"contacts":325},"Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu","Nantes",{"type":77,"coordinates":321},[322,323],-1.55336,47.21725,{"lat":323,"lon":322},[326,330],{"name":327,"role":60,"phone":328,"phoneExt":56,"email":329},"Cyrille Touzeau, MD","33 (0) 2 40 08 32 71","cyrille.touzeau@chu-nantes.fr",{"name":327,"role":89,"phone":56,"phoneExt":56,"email":56},{"facility":332,"status":70,"city":333,"state":56,"zip":56,"country":304,"countryCode":305,"cosmosGeoPoint":334,"geoPoint":338,"contacts":339},"Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers)","Poitiers",{"type":77,"coordinates":335},[336,337],0.34348,46.58261,{"lat":337,"lon":336},[340,344],{"name":341,"role":60,"phone":342,"phoneExt":56,"email":343},"Romane Giraud","+33 5 16 60 43 06","Romane.giraud@chu-poitiers.fr",{"name":345,"role":89,"phone":56,"phoneExt":56,"email":56},"Xavier Leleu, MD",{"facility":347,"status":70,"city":348,"state":56,"zip":56,"country":304,"countryCode":305,"cosmosGeoPoint":349,"geoPoint":353,"contacts":354},"Institut Universitaire du Cancer de Toulouse - Oncopole","Toulouse",{"type":77,"coordinates":350},[351,352],1.44367,43.60426,{"lat":352,"lon":351},[355],{"name":356,"role":89,"phone":56,"phoneExt":56,"email":56},"Pierre Bories, MD",{"facility":358,"status":70,"city":359,"state":360,"zip":361,"country":362,"countryCode":363,"cosmosGeoPoint":364,"geoPoint":368,"contacts":369},"Clínica Universidad de Navarra","Pamplona","Navarre","31008","Spain","ES",{"type":77,"coordinates":365},[366,367],-1.64323,42.81687,{"lat":367,"lon":366},[370,373],{"name":371,"role":60,"phone":56,"phoneExt":56,"email":372},"Ana Valcarcel","avalcarcelg@unav.es",{"name":374,"role":89,"phone":56,"phoneExt":56,"email":56},"Paula Rodriguez, MD, PhD",{"facility":376,"status":70,"city":377,"state":56,"zip":56,"country":362,"countryCode":363,"cosmosGeoPoint":378,"geoPoint":382,"contacts":383},"Hospital ClÃ-nic de Barcelona","Barcelona",{"type":77,"coordinates":379},[380,381],2.15899,41.38879,{"lat":381,"lon":380},[384,388],{"name":385,"role":60,"phone":386,"phoneExt":56,"email":387},"Julio Vidal","+34 93 227 5484","contratoshemato@recerca.clinic.cat",{"name":389,"role":89,"phone":56,"phoneExt":56,"email":56},"Laura Rosinol, MD, PhD",{"facility":391,"status":70,"city":392,"state":56,"zip":56,"country":362,"countryCode":363,"cosmosGeoPoint":393,"geoPoint":397,"contacts":398},"Hospital Universitario 12 de Octubre","Madrid",{"type":77,"coordinates":394},[395,396],-3.70256,40.4165,{"lat":396,"lon":395},[399,403,407],{"name":400,"role":60,"phone":401,"phoneExt":56,"email":402},"Joaquín Martínez López, MD","+34 91 779 2877","jmarti01@med.ucm.es",{"name":404,"role":60,"phone":405,"phoneExt":56,"email":406},"Lucía Sánchez Pérez","(+34) 91 779 28 09","luciasanchez12imas@gmail.com",{"name":400,"role":89,"phone":56,"phoneExt":56,"email":56},{"facility":409,"status":70,"city":410,"state":56,"zip":56,"country":362,"countryCode":363,"cosmosGeoPoint":411,"geoPoint":415,"contacts":416},"Instituto de Investigacion Biomedica de Salamanca (IBSAL)","Salamanca",{"type":77,"coordinates":412},[413,414],-3.67975,40.42972,{"lat":414,"lon":413},[417,422],{"name":418,"role":60,"phone":419,"phoneExt":420,"email":421},"Carmen Arias","+34 92 329 1100","56094","ensayosclinicos@ibsal.es",{"name":423,"role":89,"phone":56,"phoneExt":56,"email":56},"Maria-Victoria Mateos Manteca, MD, PhD",{"type":425,"investigatorFullName":56,"investigatorTitle":56,"investigatorAffiliation":56,"oldNameTitle":56,"oldOrganization":56},"SPONSOR",[427],{"name":428,"class":6},"Bristol-Myers Squibb","100489347","phase-1-a-study-of-an-mmset-inhibitor-in-patients-with-relapsed-and-refractory-multiple-myeloma-100489347",false,"NCT05651932","A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma","Key Inclusion Criteria for Dose-Expansion:\n\n* ≥ 18 years of age\n* ECOG score ≤ 1\n* Multiple myeloma (as per IMWG)\n\n  * Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antibody. For mezigdomide combination Cohorts B1 and B2, participants must have received at least 2 prior lines of therapy\n  * Participants must have a confirmed diagnosis of progressive MM (per IMWG), t(4;14) confirmed by fluorescence in situ hybridization (FISH) testing performed in a centralized Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory via fresh tumor biopsy.\n* Measurable disease, including at least 1 of the following criteria:\n\n  * Serum M protein ≥ 0.50 g\u002FdL (by SPEP)\n  * Serum IgA ≥ 0.50 g\u002FdL (IgA myeloma patients)\n  * Urine M protein ≥ 200 mg\u002F24 h (by UPEP)\n  * sFLC involved light chain ≥ 10 mg\u002FdL (100 mg\u002FL) (patients with abnormal sFLC ratio)\n  * Bone marrow plasma cells ≥ 30% (if only criterion for measurability)\n* Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only)\n\nKey Exclusion Criteria for Dose-Expansion:\n\n* Treatment with the following therapies in the specified time period prior to first dose:\n\n  * Patients in Cohorts B1 and B2 must not have received prior mezigdomide treatment\n  * Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2\n  * Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D\n  * Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks\n  * Cellular therapies ≤ 8 weeks\n  * Autologous transplant \\\u003C 100 days\n  * Allogenic transplant ≤ 6 months, or \\> 6 months with active GVHD\n  * Major surgery ≤ 4 weeks\n* Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis\n* Active CNS disease: participants with previously treated stable CNS disease are eligible, except for Cohorts B1 and B2 for which known CNS myeloma involvement is completely excluded.\n* Inadequate bone marrow function\n* Inadequate renal, hepatic, pulmonary, and cardiac function\n* Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.\n* Use of acid reducing agents and strong inhibitors or inducers of CYP3A4 within 7 days or 5 half-lives (whichever is longer) prior to first dose\n* Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)\n* Active malignancy not related to myeloma requiring therapy within \\\u003C 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.","ALL","18 Years",{"count":439,"type":440},165,"ESTIMATED","INTERVENTIONAL",[443],"PHASE1","A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2\u002FWHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).",[446,447,448],"Multiple Myeloma","Myeloma","Myeloma Multiple",[450,451,452,453,454,455,456,457],"NSD2","MMSET","WHSC1","T4;14","T(4;14)","translocation","myeloma","RRMM","2026-06-04",{"date":460,"type":461},"2026-06-08","ACTUAL",{"date":463,"type":461},"2023-02-22",{"date":465,"type":440},"2028-06-30",{"name":5,"class":6},22]